Concepts (213)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enterocolitis, Pseudomembranous | 6 | 2016 | 93 | 2.130 |
Why?
|
| Diarrhea | 7 | 2023 | 317 | 1.550 |
Why?
|
| Norovirus | 6 | 2015 | 317 | 1.440 |
Why?
|
| Caliciviridae Infections | 5 | 2015 | 328 | 1.230 |
Why?
|
| Gastroenteritis | 5 | 2011 | 348 | 1.140 |
Why?
|
| Travel | 4 | 2010 | 114 | 0.930 |
Why?
|
| Irritable Bowel Syndrome | 2 | 2023 | 205 | 0.840 |
Why?
|
| Immunocompromised Host | 2 | 2015 | 294 | 0.680 |
Why?
|
| Cross Infection | 4 | 2014 | 326 | 0.590 |
Why?
|
| Histoplasmosis | 2 | 2008 | 48 | 0.560 |
Why?
|
| Antifungal Agents | 4 | 2015 | 290 | 0.540 |
Why?
|
| Spores, Bacterial | 1 | 2016 | 24 | 0.500 |
Why?
|
| Organ Transplantation | 2 | 2015 | 168 | 0.500 |
Why?
|
| Echinocandins | 2 | 2015 | 44 | 0.490 |
Why?
|
| Candidemia | 1 | 2015 | 40 | 0.460 |
Why?
|
| Secondary Prevention | 1 | 2016 | 217 | 0.450 |
Why?
|
| Rifamycins | 3 | 2010 | 21 | 0.420 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 508 | 0.380 |
Why?
|
| Food Microbiology | 2 | 2009 | 24 | 0.380 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2012 | 63 | 0.380 |
Why?
|
| Enterobacteriaceae | 2 | 2009 | 35 | 0.380 |
Why?
|
| Anti-Infective Agents | 3 | 2016 | 264 | 0.370 |
Why?
|
| Histoplasma | 2 | 2008 | 31 | 0.360 |
Why?
|
| Itraconazole | 2 | 2008 | 25 | 0.350 |
Why?
|
| Dysentery | 1 | 2010 | 4 | 0.340 |
Why?
|
| Restaurants | 2 | 2009 | 15 | 0.320 |
Why?
|
| Antidiarrheals | 1 | 2009 | 17 | 0.310 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2015 | 1096 | 0.280 |
Why?
|
| Benzoxazines | 1 | 2007 | 23 | 0.280 |
Why?
|
| Colitis | 1 | 2009 | 153 | 0.280 |
Why?
|
| Anti-Bacterial Agents | 4 | 2014 | 2429 | 0.270 |
Why?
|
| Disease Outbreaks | 1 | 2009 | 320 | 0.270 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 2906 | 0.270 |
Why?
|
| Bacterial Infections | 1 | 2010 | 306 | 0.270 |
Why?
|
| Soft Tissue Infections | 1 | 2008 | 85 | 0.270 |
Why?
|
| Vegetables | 1 | 2008 | 262 | 0.260 |
Why?
|
| Transplantation Conditioning | 1 | 2008 | 279 | 0.250 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2007 | 235 | 0.250 |
Why?
|
| Humans | 31 | 2023 | 125331 | 0.230 |
Why?
|
| Clostridium Infections | 3 | 2014 | 245 | 0.230 |
Why?
|
| Hospitals, University | 3 | 2014 | 98 | 0.220 |
Why?
|
| Crohn Disease | 2 | 2017 | 279 | 0.210 |
Why?
|
| Age of Onset | 2 | 2017 | 601 | 0.210 |
Why?
|
| Male | 19 | 2017 | 61573 | 0.200 |
Why?
|
| Feces | 4 | 2015 | 727 | 0.200 |
Why?
|
| Constipation | 1 | 2023 | 114 | 0.190 |
Why?
|
| Adult | 16 | 2022 | 29607 | 0.190 |
Why?
|
| Serotonin | 1 | 2023 | 217 | 0.190 |
Why?
|
| Community-Acquired Infections | 2 | 2014 | 241 | 0.190 |
Why?
|
| Texas | 5 | 2015 | 3582 | 0.190 |
Why?
|
| Heart Transplantation | 1 | 2008 | 859 | 0.180 |
Why?
|
| Risk Factors | 5 | 2015 | 10287 | 0.170 |
Why?
|
| Mexico | 3 | 2010 | 182 | 0.170 |
Why?
|
| Neoplasms | 1 | 2014 | 2798 | 0.160 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2014 | 365 | 0.160 |
Why?
|
| Female | 16 | 2017 | 66836 | 0.160 |
Why?
|
| Graft Rejection | 2 | 2015 | 586 | 0.150 |
Why?
|
| Diagnosis, Differential | 4 | 2016 | 1898 | 0.140 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 728 | 0.140 |
Why?
|
| Sigmoid Diseases | 1 | 2016 | 7 | 0.130 |
Why?
|
| Anus Diseases | 1 | 2016 | 12 | 0.130 |
Why?
|
| Tuberculosis, Gastrointestinal | 1 | 2016 | 8 | 0.130 |
Why?
|
| Ulcer | 1 | 2016 | 48 | 0.130 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2016 | 33 | 0.130 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 5166 | 0.120 |
Why?
|
| Prevalence | 3 | 2012 | 2466 | 0.120 |
Why?
|
| Probiotics | 2 | 2010 | 214 | 0.120 |
Why?
|
| Middle Aged | 11 | 2017 | 26807 | 0.120 |
Why?
|
| Rifampin | 1 | 2016 | 131 | 0.120 |
Why?
|
| Endoscopy, Digestive System | 1 | 2016 | 152 | 0.120 |
Why?
|
| Hospitals, Community | 1 | 2015 | 55 | 0.120 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2014 | 44 | 0.110 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2014 | 53 | 0.110 |
Why?
|
| Gram-Positive Bacteria | 1 | 2014 | 47 | 0.110 |
Why?
|
| Aged | 9 | 2016 | 19728 | 0.110 |
Why?
|
| Stomach | 1 | 2016 | 270 | 0.110 |
Why?
|
| Young Adult | 5 | 2017 | 9066 | 0.110 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2014 | 75 | 0.110 |
Why?
|
| Prospective Studies | 5 | 2016 | 6160 | 0.110 |
Why?
|
| Candidiasis, Invasive | 1 | 2014 | 19 | 0.110 |
Why?
|
| Thiazoles | 2 | 2011 | 98 | 0.110 |
Why?
|
| Gastrostomy | 1 | 2014 | 86 | 0.110 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2016 | 217 | 0.110 |
Why?
|
| Abdominal Pain | 1 | 2016 | 307 | 0.110 |
Why?
|
| Precancerous Conditions | 1 | 2016 | 284 | 0.110 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 309 | 0.100 |
Why?
|
| Transplant Recipients | 1 | 2015 | 217 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 3741 | 0.100 |
Why?
|
| Graft Survival | 1 | 2015 | 531 | 0.100 |
Why?
|
| RNA, Viral | 1 | 2015 | 538 | 0.100 |
Why?
|
| Treatment Outcome | 5 | 2016 | 12290 | 0.100 |
Why?
|
| Malnutrition | 1 | 2014 | 208 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2014 | 389 | 0.090 |
Why?
|
| Colon | 1 | 2014 | 352 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 1033 | 0.090 |
Why?
|
| Creatinine | 1 | 2013 | 391 | 0.090 |
Why?
|
| Cohort Studies | 4 | 2017 | 4837 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 2901 | 0.090 |
Why?
|
| Child | 4 | 2015 | 24575 | 0.090 |
Why?
|
| Adolescent | 6 | 2017 | 19419 | 0.090 |
Why?
|
| Immunotherapy, Active | 1 | 2010 | 18 | 0.090 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 238 | 0.090 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2014 | 303 | 0.080 |
Why?
|
| Guatemala | 1 | 2010 | 63 | 0.080 |
Why?
|
| Geography | 1 | 2010 | 115 | 0.080 |
Why?
|
| Immunization, Passive | 1 | 2010 | 120 | 0.080 |
Why?
|
| Tuberculosis | 1 | 2016 | 527 | 0.080 |
Why?
|
| Hospitals, Pediatric | 1 | 2014 | 765 | 0.080 |
Why?
|
| India | 1 | 2010 | 211 | 0.080 |
Why?
|
| Hospitalization | 2 | 2015 | 1790 | 0.080 |
Why?
|
| Prognosis | 2 | 2017 | 4677 | 0.080 |
Why?
|
| Infection Control | 1 | 2010 | 156 | 0.080 |
Why?
|
| Food Handling | 1 | 2008 | 18 | 0.080 |
Why?
|
| Enterotoxins | 1 | 2008 | 82 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2010 | 1117 | 0.070 |
Why?
|
| Hot Temperature | 1 | 2008 | 136 | 0.070 |
Why?
|
| Mycophenolic Acid | 1 | 2008 | 49 | 0.070 |
Why?
|
| Liver Cirrhosis | 1 | 2014 | 844 | 0.070 |
Why?
|
| Virulence | 1 | 2008 | 264 | 0.070 |
Why?
|
| Amphotericin B | 1 | 2008 | 90 | 0.070 |
Why?
|
| Antigens, Fungal | 1 | 2007 | 34 | 0.070 |
Why?
|
| Thoracic Wall | 1 | 2008 | 38 | 0.070 |
Why?
|
| Alkynes | 1 | 2007 | 25 | 0.070 |
Why?
|
| Debridement | 1 | 2008 | 89 | 0.070 |
Why?
|
| Tacrolimus | 1 | 2008 | 97 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 434 | 0.070 |
Why?
|
| Cyclopropanes | 1 | 2007 | 67 | 0.070 |
Why?
|
| Republic of Korea | 2 | 2017 | 37 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2007 | 255 | 0.070 |
Why?
|
| Salicylates | 1 | 2006 | 54 | 0.060 |
Why?
|
| Developing Countries | 1 | 2008 | 271 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 1691 | 0.060 |
Why?
|
| Bismuth | 1 | 2006 | 80 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2011 | 520 | 0.060 |
Why?
|
| Organometallic Compounds | 1 | 2006 | 111 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 1104 | 0.060 |
Why?
|
| Fluid Therapy | 1 | 2006 | 129 | 0.060 |
Why?
|
| Time Factors | 2 | 2017 | 6318 | 0.060 |
Why?
|
| Anti-HIV Agents | 1 | 2007 | 322 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 1174 | 0.060 |
Why?
|
| Biopsy | 1 | 2008 | 1241 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 645 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2010 | 1505 | 0.050 |
Why?
|
| Control Groups | 1 | 2003 | 12 | 0.050 |
Why?
|
| Behavioral Research | 1 | 2003 | 19 | 0.050 |
Why?
|
| Diet, Gluten-Free | 1 | 2022 | 3 | 0.050 |
Why?
|
| Monosaccharides | 1 | 2022 | 23 | 0.050 |
Why?
|
| Sucrose | 1 | 2022 | 39 | 0.050 |
Why?
|
| Starch | 1 | 2022 | 25 | 0.050 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2022 | 25 | 0.050 |
Why?
|
| Network Meta-Analysis | 1 | 2022 | 28 | 0.050 |
Why?
|
| Fermentation | 1 | 2022 | 66 | 0.050 |
Why?
|
| Risk | 2 | 2014 | 759 | 0.050 |
Why?
|
| Oligosaccharides | 1 | 2022 | 75 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2014 | 14123 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 2057 | 0.050 |
Why?
|
| Nitro Compounds | 2 | 2011 | 18 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2010 | 3439 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 2089 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 3175 | 0.040 |
Why?
|
| Infant | 1 | 2014 | 12581 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 6555 | 0.040 |
Why?
|
| Azathioprine | 1 | 2017 | 54 | 0.040 |
Why?
|
| Adalimumab | 1 | 2017 | 26 | 0.040 |
Why?
|
| Mercaptopurine | 1 | 2017 | 71 | 0.030 |
Why?
|
| Infliximab | 1 | 2017 | 66 | 0.030 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2017 | 87 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2017 | 275 | 0.030 |
Why?
|
| Acetic Acid | 1 | 2016 | 18 | 0.030 |
Why?
|
| Indicators and Reagents | 1 | 2016 | 51 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2003 | 828 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2016 | 151 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 300 | 0.030 |
Why?
|
| Metaplasia | 1 | 2016 | 213 | 0.030 |
Why?
|
| Metronidazole | 1 | 2016 | 154 | 0.030 |
Why?
|
| Diet | 1 | 2022 | 1140 | 0.030 |
Why?
|
| Nanospheres | 1 | 2014 | 7 | 0.030 |
Why?
|
| Enterococcus | 1 | 2014 | 29 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2014 | 118 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2014 | 113 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 571 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2014 | 95 | 0.030 |
Why?
|
| Blood | 1 | 2014 | 104 | 0.030 |
Why?
|
| United States | 1 | 2009 | 10922 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2016 | 238 | 0.030 |
Why?
|
| Candida | 1 | 2014 | 75 | 0.030 |
Why?
|
| Intestines | 1 | 2017 | 577 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2016 | 16344 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 152 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2014 | 309 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2014 | 117 | 0.030 |
Why?
|
| Serum | 1 | 2013 | 46 | 0.030 |
Why?
|
| Vancomycin | 1 | 2014 | 217 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2014 | 315 | 0.020 |
Why?
|
| Sex Factors | 1 | 2016 | 1282 | 0.020 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 221 | 0.020 |
Why?
|
| Cholesterol | 1 | 2014 | 540 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 1808 | 0.020 |
Why?
|
| Bacteremia | 1 | 2014 | 407 | 0.020 |
Why?
|
| Aminoglycosides | 1 | 2010 | 45 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2010 | 69 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2824 | 0.020 |
Why?
|
| Ice Cream | 1 | 2009 | 2 | 0.020 |
Why?
|
| Animals | 1 | 2010 | 34298 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1292 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2014 | 1562 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 3134 | 0.020 |
Why?
|
| Cytokines | 1 | 2014 | 1288 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 731 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2011 | 503 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2010 | 797 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 3093 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2009 | 984 | 0.010 |
Why?
|